Indaptus Therapeutics Inc
INDP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$349.92M
Close$
$8.81
151.6% upside
Current Fair Value
151.6% upsideUndervalued by 151.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $349.92 Million |
|---|---|
| Enterprise Value | $342.36 Million |
| Earnings per Share | $-21.58 |
| Beta | 1.17 |
| Outstanding Shares | 116,131,213 |
Return
| Return on Equity | -135.62% |
|---|---|
| Return on Assets | -128.66% |
| Return on Invested Capital | -132.89% |
Valuation & Multiples
| P/E Ratio | -0.44 |
|---|---|
| PEG | 0.68 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -22.65 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-1.57
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-1.46
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.33% |
|---|---|
| Total Invested | $5▼ 100.00% |
| Investors Holding | 1▼ 8.00% |
About Indaptus Therapeutics Inc
40 employees
CEO: Jeffrey Meckler
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve ...